These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

125 related items for PubMed ID: 23162654

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Prediction of carboplatin clearance calculated by patient characteristics or 24-hour creatinine clearance: a comparison of the performance of three formulae.
    Okamoto H, Nagatomo A, Kunitoh H, Kunikane H, Watanabe K.
    Cancer Chemother Pharmacol; 1998; 42(4):307-12. PubMed ID: 9744776
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Performance of formulae based estimates of glomerular filtration rate for carboplatin dosing in stage 1 seminoma.
    Shepherd ST, Gillen G, Morrison P, Forte C, Macpherson IR, White JD, Mark PB.
    Eur J Cancer; 2014 Mar; 50(5):944-52. PubMed ID: 24445148
    [Abstract] [Full Text] [Related]

  • 6. Carboplatin dosing in the era of IDMS-creatinine; the Cockroft-Gault formula no longer provides a sufficiently accurate estimate of glomerular filtration rate for routine use in clinical care.
    McLean L, Whittle JR, Graham J, Ismail H, Lichtenstein M, Hicks RJ, McNally O, Herschtal A, Rosenthal M, Rischin D, Hamilton A.
    Gynecol Oncol; 2020 Jun; 157(3):793-798. PubMed ID: 32220419
    [Abstract] [Full Text] [Related]

  • 7. Analysis of carboplatin dosing in patients with a glomerular filtration rate greater than 125 mL/min: To cap or not to cap? A retrospective analysis and review.
    Morrow A, Garland C, Yang F, De Luna M, Herrington JD.
    J Oncol Pharm Pract; 2019 Oct; 25(7):1651-1657. PubMed ID: 30336729
    [Abstract] [Full Text] [Related]

  • 8. Carboplatin dosage formulae can generate inaccurate predictions of Carboplatin exposure in carboplatin/paclitaxel combination regimens.
    Nannan Panday VR, van Warmerdam LJ, Huizing MT, Ten Bokkel Huinink WW, Vermorken JB, Giaccone G, Veenhof CH, Schellens JH, Beijnen JH.
    Clin Drug Investig; 1998 Oct; 15(4):327-35. PubMed ID: 18370488
    [Abstract] [Full Text] [Related]

  • 9. Formulae recently proposed to estimate renal glomerular filtration rate improve the prediction of carboplatin clearance.
    White-Koning M, Paludetto MN, Le Louedec F, Gladieff L, Chevreau C, Chatelut E, Puisset F.
    Cancer Chemother Pharmacol; 2020 Mar; 85(3):585-592. PubMed ID: 31915969
    [Abstract] [Full Text] [Related]

  • 10. Flat dosing of carboplatin is justified in adult patients with normal renal function.
    Ekhart C, de Jonge ME, Huitema AD, Schellens JH, Rodenhuis S, Beijnen JH.
    Clin Cancer Res; 2006 Nov 01; 12(21):6502-8. PubMed ID: 17085665
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Optimizing carboplatin dosing by an improved prediction of carboplatin clearance using a CT-enhanced estimate of renal function.
    Molenaar-Kuijsten L, Pieters TT, Veldhuis WB, Moeskops P, Rijkhorst EJ, Dorlo TPC, Beijnen JH, Steeghs N, Rookmaaker MB, Huitema ADR.
    Br J Clin Pharmacol; 2023 Oct 01; 89(10):3016-3025. PubMed ID: 37194167
    [Abstract] [Full Text] [Related]

  • 13. Estimation of glomerular filtration rate in cancer patients with abnormal body composition and relation with carboplatin toxicity.
    Bretagne M, Jouinot A, Durand JP, Huillard O, Boudou Rouquette P, Tlemsani C, Arrondeau J, Sarfati G, Goldwasser F, Alexandre J.
    Cancer Chemother Pharmacol; 2017 Jul 01; 80(1):45-53. PubMed ID: 28508095
    [Abstract] [Full Text] [Related]

  • 14. Carboplatin dose calculation in lung cancer patients with low serum creatinine concentrations using CKD-EPI and Cockcroft-Gault with different weight descriptors.
    Kaag D.
    Lung Cancer; 2013 Jan 01; 79(1):54-8. PubMed ID: 23131495
    [Abstract] [Full Text] [Related]

  • 15. Glomerular filtration rate estimation for carboplatin dosing in patients with gynaecological cancers.
    Samani A, Bennett R, Eremeishvili K, Kalofonou F, Whear S, Montes A, Kristeleit R, Krell J, McNeish I, Ghosh S, Tookman L.
    ESMO Open; 2022 Apr 01; 7(2):100401. PubMed ID: 35227967
    [Abstract] [Full Text] [Related]

  • 16. Prospective evaluation of carboplatin AUC dosing in patients with a BMI>or=27 or cachexia.
    Herrington JD, Tran HT, Riggs MW.
    Cancer Chemother Pharmacol; 2006 Jan 01; 57(2):241-7. PubMed ID: 16133538
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Evaluation of predictive formulae for glomerular filtration rate for carboplatin dosing in gynecological malignancies.
    de Lemos ML, Hsieh T, Hamata L, Levin A, Swenerton K, Djurdjev O, Vu T, Hu F, Conklin J, Malfair Taylor SC.
    Gynecol Oncol; 2006 Dec 01; 103(3):1063-9. PubMed ID: 16875719
    [Abstract] [Full Text] [Related]

  • 19. Evaluation of formulas using the serum creatinine level to calculate the optimal dosage of carboplatin.
    van Warmerdam LJ, Rodenhuis S, ten Bokkel Huinink WW, Maes RA, Beijnen JH.
    Cancer Chemother Pharmacol; 1996 Dec 01; 37(3):266-70. PubMed ID: 8529288
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.